The incidence of sexually transmitted infections (STI) continues to be a global health problem. New and novel strategies are needed to reduce the incidence of STI, particularly in women as they often suffer from severe medical complications as a result of such infections. Our long-term goal is to understand the mechanisms of the innate host defense system that functions at mucosal surfaces in response to Neisseria gonorrhoeae. Antimicrobial peptides (AP) produced by phagocytic and epithelial cells are now recognized as important mediators of innate immunity. Due to their potent activity in vitro, we hypothesize that they could be engineered as topical microbicides for use in the prevention of STI. Towards that end, we are interested in how these peptides exert antigonococcal activity in vitro and how gonococci might subvert their antibiotic-like action through genetic and physiologic processes. The human AP termed LL-37 has been shown by us to exert potent action in vitro against N. gonorrhoeae and can block infection by Treponema pallidum in a rabbit skin lesion model. We have recently engineered truncated versions of LL-37 that maintain antigonococcal activity in vitro without killing lactobacilli, which are important members of the vaginal normal flora. In order to understand how LL-37 contributes to innate immunity during STI, we will design nontoxic variants of LL-37 that have enhanced capacities to kill bacterial pathogens (N. gonorrhoeae, Haemophilus ducreyi, T. pallidum and Chlamydia trachomatis) in vitro and in vivo but remain inactive against lactobacilli (Specific Aim 1). As is the case with other antibiotics, it is likely that bacterial pathogens can develop mechanisms to resist the action of AP. We will use the gonococcus as a model STI pathogen to examine this issue in order to identify the genes that may endow bacteria with the ability to constitutively (Specific Aim 2) or inducibly (Specific Aim 3) resist the action of LL-37.We will use transposon mutagenesis techniques in Specific Aim 2 and the micro array technology in Specific Aim 3 to identify these determinants. The results from our studies should generate novel compounds that could be used as topical microbicides to block STI, provide a better understanding of innate immunity at the genital mucosal surface during STI and result in important insights regarding bacterial responses to AP in vivo.

Agency
National Institute of Health (NIH)
Institute
National Institute of Allergy and Infectious Diseases (NIAID)
Type
Research Project (R01)
Project #
5R01AI062755-03
Application #
7151196
Study Section
Special Emphasis Panel (ZRG1-IDM-N (90))
Program Officer
Deal, Carolyn D
Project Start
2004-12-01
Project End
2009-11-30
Budget Start
2006-12-01
Budget End
2007-11-30
Support Year
3
Fiscal Year
2007
Total Cost
$324,989
Indirect Cost
Name
Emory University
Department
Microbiology/Immun/Virology
Type
Schools of Medicine
DUNS #
066469933
City
Atlanta
State
GA
Country
United States
Zip Code
30322
Zähner, Dorothea; Zhou, Xiaoliu; Chancey, Scott T et al. (2010) Human antimicrobial peptide LL-37 induces MefE/Mel-mediated macrolide resistance in Streptococcus pneumoniae. Antimicrob Agents Chemother 54:3516-9
Zughaier, Susu M; Svoboda, Pavel; Pohl, Jan et al. (2010) The human host defense peptide LL-37 interacts with Neisseria meningitidis capsular polysaccharides and inhibits inflammatory mediators release. PLoS One 5:e13627
Kamal, Nazia; Shafer, William M (2010) Biologic activities of the TolC-like protein of Neisseria meningitidis as assessed by functional complementation in Escherichia coli. Antimicrob Agents Chemother 54:506-8
Lewis, Lisa A; Choudhury, Biswa; Balthazar, Jacqueline T et al. (2009) Phosphoethanolamine substitution of lipid A and resistance of Neisseria gonorrhoeae to cationic antimicrobial peptides and complement-mediated killing by normal human serum. Infect Immun 77:1112-20
Garvin, Lotisha E; Bash, Margaret C; Keys, Christine et al. (2008) Phenotypic and genotypic analyses of Neisseria gonorrhoeae isolates that express frequently recovered PorB PIA variable region types suggest that certain P1a porin sequences confer a selective advantage for urogenital tract infection. Infect Immun 76:3700-9
Warner, Douglas M; Shafer, William M; Jerse, Ann E (2008) Clinically relevant mutations that cause derepression of the Neisseria gonorrhoeae MtrC-MtrD-MtrE Efflux pump system confer different levels of antimicrobial resistance and in vivo fitness. Mol Microbiol 70:462-78
Kamal, Nazia; Rouquette-Loughlin, Corinne; Shafer, William M (2007) The TolC-like protein of neisseria meningitidis is required for extracellular production of the repeats-in-toxin toxin FrpC but not for resistance to antimicrobials recognized by the Mtr efflux pump system. Infect Immun 75:6008-12
Warner, Douglas M; Folster, Jason P; Shafer, William M et al. (2007) Regulation of the MtrC-MtrD-MtrE efflux-pump system modulates the in vivo fitness of Neisseria gonorrhoeae. J Infect Dis 196:1804-12
Tzeng, Yih-Ling; Ambrose, Karita D; Zughaier, Susu et al. (2005) Cationic antimicrobial peptide resistance in Neisseria meningitidis. J Bacteriol 187:5387-96
Rouquette-Loughlin, Corinne E; Balthazar, Jacqueline T; Shafer, William M (2005) Characterization of the MacA-MacB efflux system in Neisseria gonorrhoeae. J Antimicrob Chemother 56:856-60